China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China · Delayed Price · Currency is CNY 18.56
+0.15 (0.81%)
Apr 8, 2026, 3:00 PM CST
SHA:600062 Revenue
In the year 2025, China Resources Double-Crane Pharmaceutical had annual revenue of 11.00B CNY, down -1.88%. China Resources Double-Crane Pharmaceutical had revenue of 2.72B in the quarter ending December 31, 2025, with 2.03% growth.
Revenue
11.00B
Revenue Growth
-1.88%
P/S Ratio
1.74
Revenue / Employee
820.10K
Employees
13,414
Market Cap
19.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.00B | -210.83M | -1.88% |
| Dec 31, 2024 | 11.21B | -98.52M | -0.87% |
| Dec 31, 2023 | 11.31B | 1.68B | 17.50% |
| Dec 31, 2022 | 9.63B | 513.80M | 5.64% |
| Dec 31, 2021 | 9.11B | 607.58M | 7.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 15.22B |
| Shandong Buchang Pharmaceuticals | 10.96B |
| Apeloa Pharmaceutical Co.,Ltd | 9.78B |
| Tasly Pharmaceutical Group | 8.24B |
| Betta Pharmaceuticals | 3.26B |
| Tonghua Dongbao Pharmaceutical | 2.74B |
| Walvax Biotechnology | 2.42B |
| Jilin Aodong Pharmaceutical Group | 2.34B |